{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:10:44Z","timestamp":1782133844314,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To evaluate the efficacy and safety of vonoprazan\u2013amoxicillin (VA) dual therapy for radically eradicating <jats:italic>Helicobacter pylori<\/jats:italic> (<jats:italic>H. pylori<\/jats:italic>).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The PubMed, Cochrane Library, Embase, China National\u00a0Knowledge \u00a0Infrastructure (CNKI) and Wanfang databases were searched up to July 7, 2022, to identify clinical trials comparing the efficacy of VA dual therapy and triple therapy for <jats:italic>H. pylori<\/jats:italic> eradication. After evaluating the quality of the included studies, random effects models were conducted, and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated to estimate the efficacy and safety of each approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Six publications (including four randomized controlled trials) involving 2019 patients were included in this meta-analysis. Overall, the eradication rate for VA dual therapy was 89.9%, while it was 85.2% for triple therapy based on other acid inhibitors. The eradication rate of <jats:italic>H. pylori<\/jats:italic> in the VA dual regimen group was higher than that in the PPI-based (omeprazole or lansoprazole) triple therapy group (RR\u2009=\u20091.15, 95% CI 1.07\u20131.23, p\u2009&lt;\u20090.0001). However, the efficacy of VA dual therapy was comparable with VA\u2013Clarithromycin (VAC) triple therapy (RR\u2009=\u20090.97, 95% CI 0.93\u20131.02). Besides, the incidence of adverse reactions in VA dual therapy was also lower than that in triple therapy (RR\u2009=\u20090.80, 95% CI 0.70\u20130.91, p\u2009=\u20090.0009).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Compared with PPI-based triple therapy, VA dual therapy showed a better therapeutic effect, safety and patient compliance rate for eradicating <jats:italic>H. pylori<\/jats:italic>, which should be used as a novel curative strategy in the future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-023-01249-6","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T07:02:14Z","timestamp":1691391734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The efficacy and safety of vonoprazan\u2013amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"28","author":[{"given":"Jia-Hui","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Jia","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Li","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Lu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"issue":"2","key":"1249_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","volume":"153","author":"JKY Hooi","year":"2017","unstructured":"Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2017.04.022.","journal-title":"Gastroenterology"},{"issue":"12","key":"1249_CR2","doi-asserted-by":"publisher","first-page":"e888","DOI":"10.1016\/S2468-2667(21)00164-X","volume":"6","author":"L Yang","year":"2021","unstructured":"Yang L, Kartsonaki C, Yao P, de Martel C, Plummer M, Chapman D, Guo Y, Clark S, Walters RG, Chen Y, Pei P, Lv J, Yu C, Jeske R, Waterboer T, Clifford GM, Franceschi S, Peto R, Hill M, Li L, Millwood IY, Chen Z, China Kadoorie Biobank Collaborative Group. The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study. Lancet Public Health. 2021;6(12):e888\u201396. https:\/\/doi.org\/10.1016\/S2468-2667(21)00164-X.","journal-title":"Lancet Public Health."},{"issue":"9","key":"1249_CR3","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.3390\/cells10092191","volume":"10","author":"J Baj","year":"2021","unstructured":"Baj J, Forma A, Flieger W, Morawska I, Michalski A, Buszewicz G, Sitarz E, Portincasa P, Garruti G, Flieger M, Teresi\u0144ski G. Helicobacter pylori infection and extragastric diseases-a focus on the central nervous system. Cells. 2021;10(9):2191. https:\/\/doi.org\/10.3390\/cells10092191.","journal-title":"Cells"},{"issue":"9","key":"1249_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/apt.14319","volume":"46","author":"Y Hu","year":"2017","unstructured":"Hu Y, Wan JH, Li XY, Zhu Y, Graham DY, Lu NH. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther. 2017;46(9):773\u20139. https:\/\/doi.org\/10.1111\/apt.14319.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1249_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/jgh.14947","volume":"35","author":"Y Du","year":"2020","unstructured":"Du Y, Zhu H, Liu J, Li J, Chang X, Zhou L, Chen M, Lu N, Li Z. Consensus on eradication of Helicobacter pylori and prevention and control of gastric cancer in China (2019, Shanghai). J Gastroenterol Hepatol. 2020;35(4):624\u20139. https:\/\/doi.org\/10.1111\/jgh.14947.","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"1249_CR6","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1473-3099(19)30272-5","volume":"19","author":"JM Liou","year":"2019","unstructured":"Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, Chang CY, Hsu YC, Chen MJ, Chen CC, Lee JY, Yang TH, Luo JC, Chen CY, Hsu WF, Chen YN, Wu JY, Lin JT, Lu TP, Chuang EY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019;19(10):1109\u201320. https:\/\/doi.org\/10.1016\/S1473-3099(19)30272-5.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"1249_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75(4):439\u201343. https:\/\/doi.org\/10.1007\/s40265-015-0368-z.","journal-title":"Drugs"},{"issue":"9","key":"1249_CR8","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439\u201346. https:\/\/doi.org\/10.1136\/gutjnl-2015-311304.","journal-title":"Gut"},{"issue":"2","key":"1249_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.04.012","volume":"161","author":"T Rokkas","year":"2021","unstructured":"Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O\u2019Morain C, Graham DY. Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori Infection: a network meta-analysis. Gastroenterology. 2021;161(2):495-507.e4. https:\/\/doi.org\/10.1053\/j.gastro.2021.04.012.","journal-title":"Gastroenterology"},{"issue":"2","key":"1249_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12456","volume":"23","author":"S Sue","year":"2018","unstructured":"Sue S, Ogushi M, Arima I, Kuwashima H, Nakao S, Naito M, Komatsu K, Kaneko H, Tamura T, Sasaki T, Kondo M, Shibata W, Maeda S. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial. Helicobacter. 2018;23(2): e12456. https:\/\/doi.org\/10.1111\/hel.12456.","journal-title":"Helicobacter"},{"key":"1249_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535. https:\/\/doi.org\/10.1136\/bmj.b2535.","journal-title":"BMJ"},{"key":"1249_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"issue":"9","key":"1249_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"1249_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019\u201326. https:\/\/doi.org\/10.1136\/gutjnl-2019-319954.","journal-title":"Gut"},{"issue":"3","key":"1249_CR15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","volume":"163","author":"WD Chey","year":"2022","unstructured":"Chey WD, M\u00e9graud F, Laine L, L\u00f3pez LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608\u201319. https:\/\/doi.org\/10.1053\/j.gastro.2022.05.055.","journal-title":"Gastroenterology"},{"issue":"4 Part 11","key":"1249_CR16","doi-asserted-by":"publisher","first-page":"965","DOI":"10.12669\/pjms.38.4.5436","volume":"38","author":"BF Zuberi","year":"2022","unstructured":"Zuberi BF, Ali FS, Rasheed T, Bader N, Hussain SM, Saleem A. Comparison of vonoprazan and amoxicillin dual therapy with standard triple therapy with proton pump inhibitor for Helicobacter Pylori eradication: a randomized control trial. Pak J Med Sci. 2022;38(4 Part 11):965\u20139. https:\/\/doi.org\/10.12669\/pjms.38.4.5436.","journal-title":"Pak J Med Sci."},{"issue":"6","key":"1249_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1159\/000502287","volume":"101","author":"T Furuta","year":"2020","unstructured":"Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, Tani S, Hamaya Y, Iwaizumi M, Miyajima H, Umemura K, Osawa S, Sugimoto K. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion. 2020;101(6):743\u201351. https:\/\/doi.org\/10.1159\/000502287.","journal-title":"Digestion"},{"issue":"10","key":"1249_CR18","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00535-020-01709-4","volume":"55","author":"T Gotoda","year":"2020","unstructured":"Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-na\u00efve cohort of junior high school students in Japan. J Gastroenterol. 2020;55(10):969\u201376. https:\/\/doi.org\/10.1007\/s00535-020-01709-4.","journal-title":"J Gastroenterol"},{"issue":"01","key":"1249_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.14163\/j.cnki.11-5547\/r.2021.01.052","volume":"16","author":"J Chen","year":"2021","unstructured":"Chen J. Efficacy and safety of vonoprazan and amoxicillin for the treatment of Helicobacter pylori-infected gastric ulcer. China PracMed. 2021;16(01):125\u20137. https:\/\/doi.org\/10.14163\/j.cnki.11-5547\/r.2021.01.052.","journal-title":"China PracMed"},{"issue":"1","key":"1249_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12876-017-0579-8","volume":"17","author":"JY Chang","year":"2017","unstructured":"Chang JY, Shim KN, Tae CH, Lee KE, Lee J, Lee KH, Moon CM, Kim SE, Jung HK, Jung SA. Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. BMC Gastroenterol. 2017;17(1):16. https:\/\/doi.org\/10.1186\/s12876-017-0579-8.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"1249_CR21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/apt.13497","volume":"43","author":"I Thung","year":"2016","unstructured":"Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514\u201333. https:\/\/doi.org\/10.1111\/apt.13497.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1249_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.gastro.2019.04.011","volume":"157","author":"CA Fallone","year":"2019","unstructured":"Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157(1):44\u201353. https:\/\/doi.org\/10.1053\/j.gastro.2019.04.011.","journal-title":"Gastroenterology"},{"issue":"12","key":"1249_CR23","doi-asserted-by":"publisher","first-page":"175628481985851","DOI":"10.1177\/1756284819858511","volume":"4","author":"H Mori","year":"2019","unstructured":"Mori H, Suzuki H, Omata F, Masaoka T, Asaoka D, Kawakami K, Mizuno S, Kurihara N, Nagahara A, Sakaki N, Ito M, Kawamura Y, Suzuki M, Shimada Y, Sasaki H, Matsuhisa T, Torii A, Nishizawa T, Mine T, Ohkusa T, Kawai T, Tokunaga K, Takahashi S. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Therap Adv Gastroenterol. 2019;4(12):1756284819858511. https:\/\/doi.org\/10.1177\/1756284819858511.","journal-title":"Therap Adv Gastroenterol"},{"key":"1249_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15917","author":"Y Ouyang","year":"2022","unstructured":"Ouyang Y, Wang M, Xu YL, Zhu Y, Lu NH, Hu Y. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022. https:\/\/doi.org\/10.1111\/jgh.15917.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"1249_CR25","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1111\/jgh.15572","volume":"36","author":"T Horii","year":"2021","unstructured":"Horii T, Suzuki S, Takano C, Shibuya H, Ichijima R, Kusano C, Ikehara H, Gotoda T. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2021;36(12):3314\u201321. https:\/\/doi.org\/10.1111\/jgh.15572.","journal-title":"J Gastroenterol Hepatol"},{"key":"1249_CR26","doi-asserted-by":"publisher","first-page":"881968","DOI":"10.3389\/fcimb.2022.881968","volume":"12","author":"Y Hu","year":"2022","unstructured":"Hu Y, Xu X, Ouyang YB, He C, Li NS, Xie C, Peng C, Zhu ZH, Shu X, Xie Y, Lu NH, Zhu Y. Altered gut microbiota and short-chain fatty acids after vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication. Front Cell Infect Microbiol. 2022;12:881968. https:\/\/doi.org\/10.3389\/fcimb.2022.881968.","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"1249_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/cpdd.1009","volume":"11","author":"DJ Mulford","year":"2022","unstructured":"Mulford DJ, Leifke E, Hibberd M, Howden CW. The effect of food on the pharmacokinetics of the potassium-competitive acid blocker vonoprazan. Clin Pharmacol Drug Dev. 2022;11(2):278\u201384. https:\/\/doi.org\/10.1002\/cpdd.1009.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"1249_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12788","volume":"26","author":"H Eto","year":"2021","unstructured":"Eto H, Suzuki S, Kusano C, Ikehara H, Ichijima R, Ito H, Kawabe K, Kawamura M, Yoda Y, Nakahara M, Gotoda T. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter. 2021;26(2): e12788. https:\/\/doi.org\/10.1111\/hel.12788.","journal-title":"Helicobacter"},{"issue":"9","key":"1249_CR29","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s12325-016-0374-x","volume":"33","author":"Y Sakurai","year":"2016","unstructured":"Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S. Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized. Crossover Study Adv Ther. 2016;33(9):1519\u201335. https:\/\/doi.org\/10.1007\/s12325-016-0374-x.","journal-title":"Crossover Study Adv Ther"},{"issue":"6","key":"1249_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1099\/00222615-44-6-425","volume":"44","author":"JE Sj\u00f6str\u00f6m","year":"1996","unstructured":"Sj\u00f6str\u00f6m JE, Larsson H. Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant. J Med Microbiol. 1996;44(6):425\u201333. https:\/\/doi.org\/10.1099\/00222615-44-6-425.","journal-title":"J Med Microbiol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01249-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01249-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01249-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T23:39:25Z","timestamp":1700264365000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01249-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1249"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01249-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"12 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"272"}}